Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R/R)Befloxatone SCHEMBL9482918 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| Befloxatone SCHEMBL464941 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| (R/R)Befloxatone SCHEMBL9463614 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| (R/R)Befloxatone SCHEMBL6455164 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| (R/R)Befloxatone SCHEMBL3699065 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| (R/R)Befloxatone SCHEMBL9462907 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| (R/R)Befloxatone SCHEMBL9463708 | 1.00 | GRM2 (0.53) | GRM2MAOB | |
| SCHEMBL9484172 | 0.93 | GRM2 (0.52) | GRM2MAOB | |
| SCHEMBL9484176 | 0.93 | GRM2 (0.52) | GRM2MAOB | |
| SCHEMBL9465260 | 0.90 | GRM2 (0.51) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-5264443-A | Psychotropic drugs, antidepressants and anxiolytic agents | DELALANDE S.A. (FR) | 1993-11-23 | — | — | US | disclosed |
| US-5196543-A | Antidepressants, tranquilizers | DELALANDE S.A. (FR) | 1993-03-23 | — | — | US | disclosed |
| US-5036091-A | Psychotropic drugs | DELALANDE S.A. (FR) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | GRM2 3310/4885MAOB 2570/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | GRM2 3310/4885MAOB 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.